Revolutionizing Autism Treatment: Breakthrough Therapy Shows Promising Results in Groundbreaking Study!
Stalicla SA, a Swiss neuro precision biotech company specializing in precision medicine for neuropsychiatric and neurodevelopmental disorders, has announced the publication of a significant phase 1b study on STP1. This novel combination therapy is tailored for treating a specific subgroup of patients with autism spectrum disorder (ASD) known as ASD Phenotype 1 (ASD-Phen1). Published in … Read more